04/06/2024 Prostaglandin analogue with timolol fixed-dose combination eye drops for treatment of open-angle glaucoma or ocular hypertension
The Ministry of Health’s Drug Advisory Committee has recommended:
- Latanoprost/timolol 0.005%/0.5% eye drops
in line with its registered indication for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension, in view of acceptable price proposal from the manufacturer.
Subsidy status
RLatanoprost/timolol 0.005%/0.5% eye drops is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.
NRSDL subsidy does not apply to:
- bimatoprost/timolol 0.03%/0.5% eye drops;
- tafluprost/timolol 0.0015%/0.5% eye drops; and
- travoprost/timolol 0.004%/0.05% eye drops
in view of unacceptable price proposals from the manufacturers.